Balaxi Pharmaceuticals (BALAXI) Q4 25/26 earnings summary

Executive summary

• Approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, with unmodified audit opinions from statutory auditors.

• Re-appointed internal auditors and recommended re-appointment of an independent director for a second term.

• Noted successful commissioning and licensing of the first pharmaceutical formulation plant at Jadcherla, Hyderabad, with commercialization of initial products imminent.

• Scheduled the 83rd Annual General Meeting for August 24, 2026.

Financial highlights

• Standalone revenue from operations for FY26 was ₹8,085.11 lakhs, up from ₹6,098.82 lakhs in FY25.

• Standalone net profit for FY26 was ₹514.69 lakhs, compared to a net loss of ₹117.85 lakhs in FY25.

• Consolidated revenue from operations for FY26 was ₹27,017.35 lakhs, compared to ₹29,256.12 lakhs in FY25.

• Consolidated net profit for FY26 was ₹2,507.02 lakhs, up from ₹2,766.80 lakhs in FY25.

• Earnings per share (EPS) for FY26: Standalone ₹0.93, Consolidated ₹4.54.

Outlook and guidance

• The company is prepared for commercial manufacturing of Paracetamol Tablet 500mg and Piroxicam Capsule 20mg.

• Initiated process for manufacturing permissions for 40 additional products, supporting phased expansion.

• Progressing towards WHO-GMP certification to strengthen manufacturing capabilities and future growth.